Inflammatory Cytokine-Induced Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 in Mesenchymal Stem Cells Are Critical for Immunosuppression
暂无分享,去创建一个
C. Shao | S. Shi | Yufang Shi | G. Ren | A. Roberts | A. Le | Jimin Zhang | Liying Zhang | Weifang Ling | Xin Zhao | A. L'Huillier
[1] W. Weimar,et al. Cell contact interaction between adipose‐derived stromal cells and allo‐activated T lymphocytes , 2009, European journal of immunology.
[2] Yufang Shi,et al. Species Variation in the Mechanisms of Mesenchymal Stem Cell‐Mediated Immunosuppression , 2009, Stem cells.
[3] Yufang Shi,et al. Apoptotic Cells Induce Immunosuppression through Dendritic Cells: Critical Roles of IFN-γ and Nitric Oxide1 , 2008, The Journal of Immunology.
[4] Yufang Shi,et al. Apoptotic Cells Induce Immunosuppression through Dendritic Cells: Critical Roles of Interferon‐gamma and Nitric Oxide , 2008 .
[5] R. Zhao,et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. , 2008, Cell Stem Cell.
[6] G. Lichtenstein. Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial , 2008 .
[7] Giselle Chamberlain,et al. Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing , 2007, Stem cells.
[8] A. Cope,et al. The Antiproliferative Effect of Mesenchymal Stem Cells Is a Fundamental Property Shared by All Stromal Cells1 , 2007, The Journal of Immunology.
[9] M. Haniffa,et al. Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells1 , 2007, The Journal of Immunology.
[10] S. Targan,et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. , 2007, Gastroenterology.
[11] R. Zhao,et al. Immunosuppressive properties of cloned bone marrow mesenchymal stem cells , 2007, Cell Research.
[12] Kazuya Sato,et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. , 2007, Blood.
[13] M. Yacoub,et al. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. , 2006, Tissue engineering.
[14] G. D. De Keulenaer,et al. Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. , 2006, American journal of physiology. Heart and circulatory physiology.
[15] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[16] S. Okazaki,et al. Characterization of Mesenchymal Stem Cells Isolated from Mouse Fetal Bone Marrow , 2006, Stem cells.
[17] L. Moretta,et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. , 2006, Blood.
[18] Sergio Romagnani,et al. Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .
[19] Sergio Romagnani,et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. , 2006, Stem cells.
[20] A. Lambiase,et al. Upregulation of ICAM-1 Expression in the Conjunctiva of Patients with Chronic Graft-Versus-Host Disease , 2006, European journal of ophthalmology.
[21] F. Benvenuto,et al. Human mesenchymal stem cells modulate B-cell functions. , 2006, Blood.
[22] O. Koç,et al. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. , 2005, Experimental hematology.
[23] Frank P Barry,et al. Mesenchymal stem cells avoid allogeneic rejection , 2005, Journal of Inflammation.
[24] Yi Zhang,et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. , 2005, Blood.
[25] M. Pittenger,et al. Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.
[26] J. Harlan,et al. Targeting leukocyte integrins in human diseases , 2005, Journal of leukocyte biology.
[27] Moustapha Hassan,et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.
[28] A. Straube,et al. Cerebral Endothelial Expression of Adhesion Molecules in Mice with Chronic Graft-Versus-Host Disease , 2004, Stroke.
[29] Y. Shimizu,et al. Integrins and T cell-mediated immunity. , 2004, Annual review of immunology.
[30] J. Pober,et al. T lymphocyte-endothelial cell interactions. , 2004, Annual review of immunology.
[31] L. Lindbom,et al. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. , 2003, Trends in pharmacological sciences.
[32] L. Boulet,et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. , 2003, The Journal of allergy and clinical immunology.
[33] J. Hunt,et al. Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury. , 2003, The Journal of trauma.
[34] Elizabeth Simpson,et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.
[35] T. Tedder,et al. L-Selectin or ICAM-1 Deficiency Reduces an Immediate-Type Hypersensitivity Response by Preventing Mast Cell Recruitment in Repeated Elicitation of Contact Hypersensitivity1 , 2003, The Journal of Immunology.
[36] J. Mosca,et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. , 2003, Journal of biomedical science.
[37] Subrata Ghosh,et al. Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.
[38] David H. Miller,et al. A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.
[39] O. Guntinas-Lichius,et al. Increased expression of ICAM-1, VCAM-1, MCP-1, and MIP-1α by spinal perivascular macrophages during experimental allergic encephalomyelitis in rats , 2002, BMC Immunology.
[40] Xiaoping Liu,et al. Nitric Oxide Uptake by Erythrocytes Is Primarily Limited by Extracellular Diffusion Not Membrane Resistance* , 2002, The Journal of Biological Chemistry.
[41] A. Buchman,et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease , 2002, Gut.
[42] Michael Loran Dustin,et al. The immunological synapse , 2002, Arthritis research.
[43] I. Campbell,et al. Vascular cell adhesion molecule‐1 (VCAM‐1) blockade in collagen‐induced arthritis reduces joint involvement and alters B cell trafficking , 2002, Clinical and experimental immunology.
[44] P. Smith,et al. Proteins and lipids define the diffusional field of nitric oxide. , 2001, American journal of physiology. Lung cellular and molecular physiology.
[45] R. Fujinami,et al. Contrasting effects of anti-adhesion molecule therapy in experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis , 1999, Journal of Neuroimmunology.
[46] M. Pittenger,et al. Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.
[47] K. Salmela,et al. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. , 1999, Transplantation.
[48] M. Isobe,et al. Regulation by differential development of Th1 and Th2 cells in peripheral tolerance to cardiac allograft induced by blocking ICAM-1/LFA-1 adhesion. , 1997, Circulation.
[49] Paul Wordsworth,et al. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. , 1997, British journal of rheumatology.
[50] J. R. Lancaster. A tutorial on the diffusibility and reactivity of free nitric oxide. , 1997, Nitric oxide : biology and chemistry.
[51] A. Beaudet,et al. Reduced susceptibility to collagen-induced arthritis in mice deficient in intercellular adhesion molecule-1. , 1996, Journal of immunology.
[52] G. Sobue,et al. Intrathecal administration of antibodies against LFA-1 and against ICAM-1 suppresses experimental allergic encephalomyelitis in rats. , 1996, Cellular Immunology.
[53] L. Davis,et al. Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. , 1995, Journal of immunology.
[54] M P Bevilacqua,et al. Endothelial-leukocyte adhesion molecules. , 1993, Annual review of immunology.